Paula Carolina Gädicke LHuissier

Prof. Dr. Paula Carolina Gädicke LHuissier

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in Preventive Veterinary Medicine
Verified
Journal Article
Closed access
PLPaula Carolina Gädicke LHuissier
Paula Carolina Gädicke LHuissier
RVR. Vidal
R. Vidal
GMGustavo Monti
Gustavo Monti

1 June 2013 in Preventive Veterinary Medicine
Verified
Journal Article
Closed access
PLPaula Carolina Gädicke LHuissier
Paula Carolina Gädicke LHuissier
GMGustavo Monti
Gustavo Monti

8 March 2022 in Animals
Verified
Journal Article
Open access
PDF file
PLPaula Carolina Gädicke LHuissier
Paula Carolina Gädicke LHuissier
DHDavid Heath
David Heath
AMAngela Medina-Brunet
Angela Medina-Brunet
MFMaría Carolina Siva-De la Fuente
María Carolina Siva-De la Fuente
HEHellen Espinoza-Rojas
Hellen Espinoza-Rojas
Carlos Landaeta-AquevequeCarlos Landaeta-Aqueveque
Carlos Landaeta-Aqueveque
Echinococcosis is a neglected zoonosis that uses dogs and sheep as its main hosts in Chile. The Eg95 vaccine against sheep infection has been included in some control programs. Here, we assess the efficacy of the vaccination program in the hyperendemic Alto Biobío commune after 3 years of execution. Fisher’s test and generalized linear models were used in the assessment. The program tried to offer a first dose at 2 months of age, a booster 1 month later, and yearly vaccination. Given logistic difficulties, important delays in vaccination occurred, and most animals did not receive the first booster. Dog deworming was not included in the program. Likely due to the aforementioned factors, the overall frequency of infection was not lower, but the proportion of large (>5 mm) cysts and fertile cysts was smaller after the program. The frequency of infection and/or the number of cysts were lower when the age at first dose was younger and the first booster was administered 1 month after the first dose. The results suggest that vaccination affects both cyst development after the larvae reach the target organs, as well as the development of the protoscolex once the cysts start developing.

Verified
Journal Article
Open access
PDF file
VAVerónica Avello
Verónica Avello
SSSantiago Alberto Salazar
Santiago Alberto Salazar
EHEddy Ernesto González Horta
Eddy Ernesto González Horta
PMPaula Canpos Martínez
Paula Canpos Martínez
Viana Manrique SuárezViana Manrique Suárez
Viana Manrique Suárez
RMRaquel Montesino
Raquel Montesino
Multivalent live-attenuated or inactivated vaccines are often used to control the bovine viral diarrhea disease (BVD). Still, they retain inherent disadvantages and do not provide the expected protection. This study developed a new vaccine prototype, including the external segment of the E2 viral protein from five different subgenotypes selected after a massive screening. The E2 proteins of every subgenotype (1aE2, 1bE2, 1cE2, 1dE2, and 1eE2) were produced in mammalian cells and purified by IMAC. An equimolar mixture of E2 proteins formulated in an oil-in-water adjuvant made up the vaccine candidate, inducing a high humoral response at 50, 100, and 150 µg doses in sheep. A similar immune response was observed in bovines at 50 µg. The cellular response showed a significant increase in the transcript levels of relevant Th1 cytokines, while those corresponding to the Th2 cytokine IL-4 and the negative control were similar. High levels of neutralizing antibodies against the subgenotype BVDV1a demonstrated the effectiveness of our vaccine candidate, similar to that observed in the sera of animals vaccinated with the commercial vaccine. These results suggest that our vaccine prototype could become an effective recombinant vaccine against the BVD.

4 December 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
SSSantiago Alberto Salazar
Santiago Alberto Salazar
MSMaría Francisca Starck
María Francisca Starck
MVMilton F. Villegas
Milton F. Villegas
JAJannel Acosta
Jannel Acosta
OROliberto Sanchez Ramos
Oliberto Sanchez Ramos
RMRaquel Montesino
Raquel Montesino
Previously, we designed a subunit vaccine candidate based on three L. intracellularis antigens with promising results in pigs. In this study, antigens were produced individually to achieve an even antigen ratio in the formulation. The emulsion characterization included the drop size and the mechanical and thermal stability. Immune response was evaluated by indirect and sandwich ELISAs, qPCR, and flow cytometry. The vaccine candidate’s safety was assessed by histopathology and monitoring the clinical behavior of animals. The average production yielded for the chimeric antigen as inclusion bodies was around 75 mg/L. The formulation showed mechanical and thermal stability, with a ratio Hu/Ho > 0.85 and a drop size under 0.15 nm. Antigens formulated at a ratio of 1:1:1 induced a significant immune response in inoculated pigs that persisted until the end of the experiment (week 14). The dose of 200 μg significantly activated cellular response measured by transcriptional and translational levels of cytokines. The cell proliferation assay revealed an increment of lymphocytes T CD4+ at the same dose. Animals gained weight constantly and showed proper clinical behavior during immunization assays. This research demonstrated the immunological robustness of the new subunit vaccine candidate against Porcine Proliferative Enteropathy evenly formulated with three chimeric antigens of L. intracellularis.

1 March 2013 in Revista médica de Chile
Verified
Journal Article
Open access
PDF file
TJTania Junod
Tania Junod
JLJuana López-Martin
Juana López-Martin
PLPaula Carolina Gädicke LHuissier
Paula Carolina Gädicke LHuissier